BioCentury
ARTICLE | Financial News

AcelRx planning $25M follow-on

November 21, 2012 11:36 PM UTC

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) said late Tuesday that it plans to raise up to $25 million in a follow-on. Earlier this month, AcelRx reported that its Sufentanil NanoTab PCA System met the primary endpoint of non-inferiority to IV patient-controlled analgesia with morphine in the proportion of patients with Patient Global Assessment pain control ratings of "good" or "excellent" over 48 hours after surgery in a Phase III trial to treat postoperative pain following major surgery. AcelRx expects data next quarter from a pair of Phase III trials to treat postoperative pain (see BioCentury Extra, Nov. 15). ...